2 unknown. 2 Phase 2, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 2 | Unknown 2 |
| Phase 1 | 1 | Unknown 1 |
Follow Immunicom Inc: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Immunopheresis Alone or in Combination With Paclitaxel or Atezolizumab in Non-small Cell Lung Cancer (NSCLC). LW-02 device immunopheresis combined with atezolizumab, LW-02 device immunopheresis combined with weekly paclitaxel, LW-02 device immunopheresis - Non Small Cell Lung Cancer | Phase 2 | Unknown | Immunicom Inc | 24 | 2020-10-01 | 2022-03-08 |
| A Study Comparing Immunopheresis® Alone or In Combination With Chemotherapy Versus Chemotherapy Alone in Treatment of Advanced Breast Cancer Patients Plasma soluble TNF receptor pulldown, Plasma soluble TNF receptor pulldown + chemotherapy, Chemotherapy Drugs, Cancer - Advanced Breast Cancer | Phase 1 / Phase 2 | Unknown | Immunicom Inc | 170 | 2019-05-31 | 2022-03-24 |
Breast Neoplasms (1) · Carcinoma, Non-Small-Cell Lung (1)
Drug Therapy (2) · Antineoplastic Agents (1) · Immunotherapy (1)
Turkey (Türkiye) (2) · Poland (1)